We are live on
!
Find out more
MP
Mangrove Partners Portfolio holdings
AUM
$1.24B
1-Year Est. Return
41.74%
This Fund
S&P 500
This Quarter
Est. Return
+32.76%
1 Year Est. Return
+41.74%
3 Year Est. Return
+169.22%
5 Year Est. Return
+150.23%
10 Year Est. Return
+417.9%
AUM
$410M
AUM Growth
-$315M
(-43%)
Cap. Flow
-$416M
Cap. Flow
% of AUM
-101.51%
Top 10 Holdings %
Top 10 Hldgs %
55.38%
Holding
93
New
16
Increased
4
Reduced
29
Closed
41
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PennyMac Financial
PFSI
|
+$8.75M |
| 2 |
KBR
KBR
|
+$8.75M |
| 3 |
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
|
+$7.63M |
| 4 |
BLUE
bluebird bio
BLUE
|
+$7.55M |
| 5 |
Quanta Services
PWR
|
+$5.85M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Russell 2000 ETF
IWM
|
+$224M |
| 2 |
Iovance Biotherapeutics
IOVA
|
+$26.3M |
| 3 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$24.1M |
| 4 |
PDCE
PDC Energy, Inc.
PDCE
|
+$18.6M |
| 5 |
International Seaways
INSW
|
+$18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.23% |
| 2 | Financials | 14.43% |
| 3 | Industrials | 12.86% |
| 4 | Materials | 10.92% |
| 5 | Energy | 8.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Korn Ferry
KFY
$3.98B
| $5.54M | 1.35% |
+180,437
| New | +$5.16M |
|
|
SRRA
27
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $5.09M | 1.24% |
421,089
-18,443
| -4% | -$229K |
|
28
CALL
Corbus Pharmaceuticals
CRBP
$170M
| $4.63M | 1.13% |
18,407
+15,324
| +497% | +$3.1M |
|
|
AT
29
DELISTED
Atlantic Power Corporation
AT
| $4.41M | 1.08% |
2,202,685
-5,281,504
| -71% | -$10.5M |
|
|
ROCC
30
DELISTED
Ranger Oil Corporation Class A Common Stock
ROCC
| $3.79M | 0.93% |
397,921
-1,331,461
| -77% | -$10.3M |
|
31
Immunovant
IMVT
$8.09B
| $3.17M | 0.77% |
130,307
-441,635
| -77% | -$9.46M |
|
|
NMCI
32
DELISTED
Navios Maritime Containers L.P. Common Units
NMCI
| $2.68M | 0.65% |
3,307,750
-100
| -0% | -$73 |
|
33
CALL
PG&E
PCG
$47.8B
| $2.48M | 0.61% |
280,000
-600,000
| -68% | -$6.54M |
|
34
Alpha Metallurgical Resources
AMR
$1.82B
| $2.15M | 0.52% |
706,108
| – | – |
|
|
BLU
35
DELISTED
BELLUS Health Inc.
BLU
| $2.14M | 0.52% |
207,778
-305,906
| -60% | -$3.1M |
|
36
Larimar Therapeutics
LRMR
$416M
| $1.88M | 0.46% |
146,142
-760
| -0.5% | -$8.85K |
|
37
Magnachip Semiconductor
MX
$128M
| $1.85M | 0.45% |
+179,589
| New | +$2M |
|
|
38
Iovance Biotherapeutics
IOVA
$2.23B
| $1.75M | 0.43% |
63,723
-799,654
| -93% | -$26.3M |
|
39
Progressive
PGR
$124B
| $1.63M | 0.4% |
+20,394
| New | +$1.59M |
|
|
SFBS
40
ServisFirst Bancshares
SFBS
$4.79B
| $1.57M | 0.38% |
+43,973
| New | +$1.45M |
|
41
Bank of N.T. Butterfield & Son
NTB
$2.42B
| $1.51M | 0.37% |
+61,828
| New | +$1.35M |
|
42
Ramaco Resources Class A
METC
$676M
| $1.46M | 0.36% |
707,147
-86,156
| -11% | -$204K |
|
43
Rhythm Pharmaceuticals
RYTM
$7B
| $1.27M | 0.31% |
+57,138
| New | +$1.11M |
|
|
44
PUT
PG&E
PCG
$47.8B
| $1.15M | 0.28% |
129,500
-33,300
| -20% | -$363K |
|
45
Western Alliance Bancorporation
WAL
$9.07B
| $854K | 0.21% |
+22,545
| New | +$789K |
|
|
FFWM
46
DELISTED
First Foundation Inc
FFWM
| $826K | 0.2% |
+50,547
| New | +$679K |
|
47
Stock Yards Bancorp
SYBT
$2.41B
| $567K | 0.14% |
+14,103
| New | +$460K |
|
|
EGLE
48
DELISTED
Eagle Bulk Shipping Inc.
EGLE
| $478K | 0.12% |
31,178
-38,861
| -55% | -$522K |
|
|
49
PUT
Corbus Pharmaceuticals
CRBP
$170M
| $179K | 0.04% |
+710
| New | +$143K |
|
|
GDYNW
50
DELISTED
Grid Dynamics Holdings, Inc. Warrant
GDYNW
| $161K | 0.04% |
100,856
-24,144
| -19% | -$42.3K |
|
Similar funds
GX
HCA
CA
WTA
NHAS
FLII
CCA
IC
Mangrove Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Mangrove Partners held 93 positions worth $410M, down 43% from $725M the previous quarter. Its ten largest holdings account for 55% of the portfolio.
Mangrove Partners withdrew a net $416M in Q2 2020, closing 41 positions and reducing 29 holdings. Its most notable exit was iShares Russell 2000 ETF, an estimated $224M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 17% a quarter earlier, followed by Financials and Industrials.
Against the trend, Mangrove Partners opened a new position in PennyMac Financial worth $11.5M.
- Mangrove Partners's largest Q2 2020 buy was PennyMac Financial: 276,240 shares worth $11.5M.
- Mangrove Partners added most to Bristol-Myers Squibb Company Contingent Value Rights in Q2 2020, an estimated $7.63M increase.
- Mangrove Partners's biggest Q2 2020 reduction was Iovance Biotherapeutics, cutting an estimated $26.3M.
- Mangrove Partners fully exited iShares Russell 2000 ETF in Q2 2020, selling an estimated $224M.
- Mangrove Partners's ten largest holdings make up 55% of its $410M portfolio in Q2 2020.
- Mangrove Partners opened 16 new positions and closed 41 in Q2 2020.
- Mangrove Partners's portfolio value fell 43% quarter-over-quarter to $410M.
Based on Mangrove Partners's 13F filing for Q2 2020, filed 14 Aug 2020.